Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: CDK4/6 Inhibitors in the Management of HR-Positive Breast Cancer — Nursing Symposium Proceedings

Faculty

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel CDK4/6 inhibitors for HR-positive breast cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of HR-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 21, 2026, to July 21, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith has consulting agreements with Amplity; is on speakers bureaus with AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, and Stemline Therapeutics Inc; and has nonrelevant financial relationships with ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, and Oncology Nursing News. Dr O’Regan is on advisory committees with Biotheranostics Inc, A Hologic Company; has consulting agreements with Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, and Regor Pharmaceuticals; has contracted research with Novartis and Puma Biotechnology Inc; and is on data and safety monitoring boards/committees for Gilead Sciences Inc.

MODERATOR
Dr Nanda is on advisory committees with AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, and Summit Therapeutics; and has contracted research with Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, and Relay Therapeutics.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Lilly and Novartis.

Release date: July 21, 2026
Expiration date: July 21, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Alexiou S et al. CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials. Cancers (Basel) 2025;17(21):3538. Abstract

Barrios CH et al. NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Breast 2024;Abstract 113MO.

Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med 2020;383(26):2557-70. Abstract

Crown J et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open 2025;10(11):105858. Abstract

de la Haba-Rodriquez J et al. ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria. ESMO 2024;Abstract LBA23.

Fasching PA et al. Ribociclib plus endocrine therapy in hormone receptor-positive/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol 2025;11(11):1364-72. Abstract

Goetz MP et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: Analyses from the monarchE study. NPJ Breast Cancer 2024;10(1):34. Abstract

Hamilton E et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in NATALEE. San Antonio Breast Cancer Symposium 2024;Abstract P1-11-16.

Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor-positive/HER2-/PIK3CA wild-type advanced breast cancer. J Clin Oncol 2026;44(12):1108-19. Abstract

Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract

Jhaveri KL et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med 2025;393(2):151-61. Abstract

Johnston S et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol 2026;37(2):155-65. Abstract

Johnston SRD et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(1):77-90. Abstract

Johnston SRD et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38(34):3987-98. Abstract

Kalinsky K et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4/6 inhibition: Results from the phase III postMONARCH trial. J Clin Oncol 2025;43(9):1101-12. Abstract

Kubeczko M et al. Efficacy of CDK 4/6 inhibitors and radiotherapy in breast cancer patients with brain metastases. J Clin Med 2023;12(5):2044. Abstract

Loibl S et al. Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy – PADMA study. San Antonio Breast Cancer Symposium 2024;Abstract LB1-03.

Lu Y-S et al. Final results of RIGHT Choice: Ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol 2024;42(23):2812-21. Abstract

Mayer EL et al. The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. ASCO 2025;Abstract 517.

Merz LE. A paradigm shift in neutrophil adverse event grading: Why now? Hemasphere 2025;9(10):e70242. Abstract

Metzger O et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 2026;394(5):451-62. Abstract

Metzger O et al. Central nervous system outcomes from the phase III PATINA trial (AFT-38). San Antonio Breast Cancer Symposium 2025;Abstract RF4-01.

Orlandi A. Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2- metastatic breast cancer with visceral crisis? Evaluating the emerging evidence. Discov Oncol 2025;16(1):982. Abstract

Slamon DJ et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 2024;42(9):994-1000. Abstract

Tolaney SM et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 2020;26(20):5310-9. Abstract

Turner NC et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med 2024;391(17):1584-96. Abstract